Related Experiment Video
Updated: Feb 27, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival
Suchismita Mohanty1, Zixin Chen1, Kai Li1
1Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California.
Abstract:
Glioblastoma (GBM) has a dismal prognosis. Evidence from preclinical tumor models and human trials indicates the role of GBM-initiating cells (GIC) in GBM drug resistance. Here, we propose a new treatment option with tumor enzyme-activatable, combined therapeutic and diagnostic (theranostic) nanoparticles, which caused specific toxicity against GBM tumor cells and GICs. The theranostic cross-linked iron oxide nanoparticles (CLIO) were conjugated to a highly potent vascular disrupting agent (ICT) and secured with a matrix-metalloproteinase (MMP-14) cleavable peptide. Treatment with CLIO-ICT disrupted tumor vasculature of MMP-14-expressing GBM, induced GIC apoptosis, and significantly impaired tumor growth. In addition, the iron core of CLIO-ICT enabled in vivo drug tracking with MR imaging. Treatment with CLIO-ICT plus temozolomide achieved tumor remission and significantly increased survival of human GBM-bearing mice by more than 2-fold compared with treatment with temozolomide alone. Thus, we present a novel therapeutic strategy with significant impact on survival and great potential for clinical translation. Mol Cancer Ther; 16(9); 1909-21. ©2017 AACR.
Insights
This study introduces novel theranostic nanoparticles that target glioblastoma (GBM) and its stem cells, enhancing drug resistance and improving survival. The nanoparticles offer combined therapy and diagnostics for GBM treatment.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Glioblastoma (GBM) presents a poor prognosis, with GBM-initiating cells (GICs) contributing to drug resistance.
- Current treatments for GBM have limited efficacy, highlighting the need for innovative therapeutic strategies.
Purpose of the Study:
- To develop and evaluate tumor enzyme-activatable, theranostic nanoparticles for targeted GBM therapy.
- To assess the efficacy of these nanoparticles in disrupting tumor vasculature, inducing GIC apoptosis, and inhibiting tumor growth.
Main Methods:
- Conjugation of cross-linked iron oxide nanoparticles (CLIO) with a vascular disrupting agent (ICT) and an MMP-14 cleavable peptide.
- Evaluation of CLIO-ICT treatment in GBM models, assessing tumor vasculature disruption, GIC apoptosis, tumor growth inhibition, and in vivo tracking using MR imaging.
- Combination therapy of CLIO-ICT with temozolomide in human GBM-bearing mice.
Main Results:
- CLIO-ICT specifically targeted GBM tumor cells and GICs, inducing apoptosis and significantly impairing tumor growth.
- The nanoparticles enabled in vivo tracking of drug delivery via MR imaging.
- Combination therapy with temozolomide resulted in tumor remission and more than doubled survival in GBM-bearing mice.
Conclusions:
- Novel theranostic nanoparticles show significant potential for treating GBM by targeting GICs and disrupting tumor vasculature.
- This approach offers a promising therapeutic strategy with potential for clinical translation, improving patient survival.
- The theranostic capability allows for real-time monitoring of treatment efficacy.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019